MG
KALA icon

Michael Gelband’s KALA BIO KALA Stock Holding History

Michael Gelband’s Portfolio KALA Stock Details KALA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-9
Closed -$27K – 2431
2021
Q4 		$27K Buy
+9
New +$41.8K ﹤0.01% 2076
2020
Q4 		– Sell
-5
Closed -$93K – 2171
2020
Q3 		$93K Sell
5
-3
-38% -$69K ﹤0.01% 1600
2020
Q2 		$202K Buy
+8
New +$227K 0.01% 1516

Other funds holding KALA

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BOTOTLSJU
Board of Trustees of The Leland Stanford Junior University Redwood City, California $533M AUM 65.58% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
VAFP
Vahanian & Associates Financial Planning Saratoga Springs, New York $25.3M AUM 39.42% 1-Year Est. Return
GL
Graypoint LLC Albany, New York $1.78B AUM 16.72% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Michael Gelband's KALA Position: Q1 2022 in Review

Michael Gelband sold out of KALA BIO (KALA) in Q1 2022, closing a stake of 9 shares — an estimated $27K sold.

Michael Gelband first reported a position in KALA in Q2 2020 and held it in 3 quarters. The position peaked at $202K in Q2 2020. 82 funds tracked by Wall St. Rank hold KALA as of Q1 2022.

  • Michael Gelband reported no remaining KALA BIO position as of Q1 2022 after selling out during the quarter.
  • Michael Gelband sold 9 KALA BIO shares in Q1 2022, an estimated $27K.
  • Michael Gelband first reported a position in KALA BIO in Q2 2020 and held it in 3 quarters.
  • Michael Gelband's KALA BIO position peaked at $202K in Q2 2020.
  • 82 funds tracked by Wall St. Rank held KALA BIO as of Q1 2022.

Based on ExodusPoint Capital Management's 13F filing for Q1 2022, filed 13 May 2022.